Taking a Risk-Based Approach to Drug Inspections

By Quality Digest, February 2019

As the United States struggles with rising healthcare costs, reducing the amount of money pharmaceutical companies spend dealing with regulation, while at the same time meeting drug safety requirements, would seem to be competing interests.

The goal of any honest pharmaceutical company is to make money producing a safe product that consumers need and getting it to market as quickly as possible. But the U.S. Food and Drug Administration’s (FDA) job is to make sure drugs are safe, and that means oversight (some would say excessive oversight), and oversight means costs and delays for manufacturers.

To read the complete article click here.

© 1995-2019 Sparta Systems, Inc. All Rights Reserved.
© 1995-2019 Sparta Systems, Inc. All Rights Reserved.Sparta Systems Logo